MET and non-small cell lung carcinoma: Current targets of ADCs for NSCLC that are either approved or in late-stage clinical development include human epidermal growth factor receptor 2 (HER2), trophoblast cell-surface antigen 2 (TROP2), human epidermal growth factor receptor 3 (HER3), and MET [34].